Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials

DOI: 10.2147/OTT.S186816

Keywords: bevacizumab, neoadjuvant chemotherapy, breast cancer, HER2-negative, randomized controlled trial

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text